People lose weight via three primary methods: diet and exercise, weight loss surgery and GLP-1 weight loss drugs. The ...

Adults with type 2 diabetes using a GLP-1 receptor agonist have a similar risk for developing thyroid cancer as those using a ...

Noom releases a significant update of its innovative GLP-1 companion to improve medication persistence and adherence while ...

For patients with diabetes undergoing a surgical procedure, an active perioperative glucagon-like peptide-1 receptor agonist ...

Eli Lilly and other drugmakers are reportedly planning to urge the Trump administration to pause Medicare drug-price ...

Data from Hengrui’s Phase II trial for its GLP-1/GIP product demonstrated a statistically significant mean weight loss of ...

Market News Alerts Updates that DarioHealth Corp. (Nasdaq: DRIO) is taking another bold step into the rapidly growing weight-loss market, now projected to exceed $100 billion annually by 2030. The ...

This is just a glimpse of the insights available to CivicScience clients. Want to see the full picture? Let’s talk. As the ...

Cancer researchers found that patients on GLP-1s had significant risk reductions for 10 of 13 obesity-associated cancers.

Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...

The company also dropped a clue about who is -- or isn't -- winning market share in GLP-1 drug sales. In a press release this ...

The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, ...